[go: up one dir, main page]

AU2002340010A1 - Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors - Google Patents

Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors

Info

Publication number
AU2002340010A1
AU2002340010A1 AU2002340010A AU2002340010A AU2002340010A1 AU 2002340010 A1 AU2002340010 A1 AU 2002340010A1 AU 2002340010 A AU2002340010 A AU 2002340010A AU 2002340010 A AU2002340010 A AU 2002340010A AU 2002340010 A1 AU2002340010 A1 AU 2002340010A1
Authority
AU
Australia
Prior art keywords
indazoles
substituted
lyase inhibitors
pyridyl indoles
indoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002340010A
Inventor
Donald Bierer
Michael J. Burke
Gaetan H. Ladouceur
Wai C. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of AU2002340010A1 publication Critical patent/AU2002340010A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002340010A 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors Abandoned AU2002340010A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32499301P 2001-09-26 2001-09-26
US60/324,993 2001-09-26
PCT/US2002/030482 WO2003027094A2 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors

Publications (1)

Publication Number Publication Date
AU2002340010A1 true AU2002340010A1 (en) 2003-04-07

Family

ID=23265979

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002362603A Abandoned AU2002362603A1 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
AU2002340010A Abandoned AU2002340010A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002362603A Abandoned AU2002362603A1 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors

Country Status (5)

Country Link
EP (2) EP1432698A2 (en)
JP (2) JP2005532983A (en)
AU (2) AU2002362603A1 (en)
CA (2) CA2461360A1 (en)
WO (8) WO2003027105A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4160295B2 (en) * 2000-12-08 2008-10-01 武田薬品工業株式会社 Substituted thiazole derivatives having a 3-pyridyl group, method for producing the same, and use thereof
DE60139639D1 (en) * 2000-12-08 2009-10-01 Takeda Pharmaceutical SUBSTITUTED THIAZONE DERIVATIVES WITH 3-PYRIDYL GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR USE
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
ES2222827B1 (en) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. DERIVATIVES OF 5-INDOLILSULFONAMIDS, ITS PREPARATION AND ITS APPLICATION AS MEDICINES.
WO2005049018A1 (en) * 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
JP2007532669A (en) * 2004-04-13 2007-11-15 イカジェン インコーポレイテッド Polycyclic pyrimidines as potassium ion channel modulators
JP4602686B2 (en) * 2004-04-15 2010-12-22 広栄化学工業株式会社 Process for producing 2,6-dihalogeno-4-arylpyridines
EP3067053A1 (en) 2004-10-13 2016-09-14 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
CN101065358B (en) * 2004-10-20 2015-03-11 默克雪兰诺有限公司 3-Arylaminopyridine Derivatives
WO2006051723A1 (en) * 2004-11-09 2006-05-18 Kaneka Corporation Method for producing 1-halo-3-aryl-2-propanone
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
AU2005325497A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
WO2006122011A2 (en) 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
UA97348C2 (en) * 2005-07-29 2012-02-10 4Сц Аг HETEROCYCLIC NF-kB INHIBITORS
FR2889526B1 (en) * 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
KR20080066938A (en) * 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 Nitrogen containing heterocyclic compound and pharmaceutical composition containing it
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
EP1971596A2 (en) * 2005-12-28 2008-09-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
WO2007082808A2 (en) * 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-hsd1 inhibitors
JP4912414B2 (en) * 2006-01-24 2012-04-11 イーライ リリー アンド カンパニー Indolesulfonamide-based progesterone receptor modulators
EP2001849B1 (en) * 2006-03-29 2014-11-26 F. Hoffmann-La Roche AG Pyridine and pyrimidine derivatives as mglur2 antagonists
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
ATE534642T1 (en) * 2006-09-21 2011-12-15 Eisai R&D Man Co Ltd PYRIDINE DERIVATIVE SUBSTITUTED BY A HETEROARYL RING AND ANTIFUNGAL AGENT CONTAINING SAME
EP2065377B1 (en) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
ZA200902127B (en) 2006-10-02 2010-07-28 Cortendo Invest Ab Ketoconazole enantiomer in humans
US8466154B2 (en) 2006-10-27 2013-06-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
BRPI0811939A2 (en) 2007-05-22 2014-11-25 Achillion Pharmaceuticals Inc HETEROARILY REPLACED THIAZOIS
AU2008286879B2 (en) 2007-08-13 2013-08-22 Monsanto Technology Llc Compositions and methods for controlling nematodes
AU2008310097B2 (en) 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
MX2010007604A (en) * 2008-01-11 2010-08-02 Novartis Ag Pyrimidines as kinase inhibitors.
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CN101965176B (en) 2008-02-08 2012-06-20 株式会社资生堂 Whitening agents and skin external preparations
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
UA105005C2 (en) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Compounds for the treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
AU2009282567B2 (en) * 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
BRPI0919004A2 (en) 2008-09-22 2019-09-24 Cayman Chem Co multiheteroaryl compound as h-pgds inhibitors and their use for the treatment of prostaglandin d2 mediated diseases
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102395585A (en) 2009-01-30 2012-03-28 米伦纽姆医药公司 Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CA2755660A1 (en) * 2009-03-19 2010-09-23 Sanofi Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof
JP5728487B2 (en) * 2009-10-29 2015-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic heterocyclic compounds
WO2011051198A2 (en) * 2009-10-30 2011-05-05 Bayer Cropscience Ag Pyridine derivatives as agricultural pesticides
DE102009058280A1 (en) * 2009-12-14 2011-06-16 Merck Patent Gmbh thiazole
MX377405B (en) 2010-03-01 2025-03-07 Gtx Inc COMPOUNDS FOR THE TREATMENT OF CANCER.
EP2593453B1 (en) 2010-07-15 2014-09-17 Bristol-Myers Squibb Company Azaindazole compounds
CA2807149C (en) 2010-08-04 2017-05-02 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
JP2013542941A (en) 2010-10-13 2013-11-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Heteroaryl and uses thereof
CN103270029B (en) 2010-10-22 2016-01-20 拜耳知识产权有限责任公司 As the heterogeneous ring compound of agricultural chemicals
EP2632903A4 (en) * 2010-10-28 2014-11-26 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
CN103328473A (en) 2010-11-12 2013-09-25 百时美施贵宝公司 Substituted azaindazole compounds
GB2485404A (en) * 2010-11-15 2012-05-16 Nat Univ Ireland Metal-complexed pyridyl-substituted tetrazole compounds and their use in treating cancer
CN102675286B (en) * 2011-03-07 2015-08-19 中国科学院上海药物研究所 Indazole compounds, preparation method, application and pharmaceutical composition thereof
AU2012249421B9 (en) * 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
US20120302573A1 (en) * 2011-05-25 2012-11-29 Paul Francis Jackson Methods of inhibiting pro matrix metalloproteinase activation
WO2013049263A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CA2886117C (en) 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
WO2014099833A1 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Indazole compounds as aldosterone synthase inhibitors
KR102246652B1 (en) 2013-03-05 2021-04-29 유니버시티 오브 테네시 리서치 파운데이션 Compounds for treatment of cancer
US20160022606A1 (en) 2013-03-14 2016-01-28 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
WO2016040896A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
JP7193071B2 (en) * 2017-02-08 2022-12-20 国立大学法人東海国立大学機構 Fluorescent materials and UV absorbers
CN120025336A (en) * 2019-12-18 2025-05-23 加利福尼亚大学董事会 LIN28 inhibitors and methods of use thereof
US20210246109A1 (en) * 2020-02-11 2021-08-12 University Of Kentucky Research Foundation Potent and selective inhibitors of cytochrome p450
WO2023049199A1 (en) * 2021-09-24 2023-03-30 Zeno Management, Inc. Azole compounds
CN117551029A (en) * 2023-11-22 2024-02-13 河南大学 A kind of synthetic method of 4-bromo-3-cyanopyridine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150068C (en) * 1978-06-02 1987-06-29 Pfizer METHOD OF ANALOGUE FOR THE PREPARATION OF AMINOTHIAZOLES
JPS55133366A (en) * 1979-04-05 1980-10-17 Otsuka Pharmaceut Factory Inc Thiazole derivative
US4536505A (en) * 1983-05-17 1985-08-20 Ciba-Geigy Corporation Certain N-(pyridyl) indoles
DE3940476A1 (en) * 1989-12-07 1991-06-13 Bayer Ag PYRIDINYLPYRIMIDINE DERIVATIVES
DE3940477A1 (en) * 1989-12-07 1991-06-13 Bayer Ag HETARYL-SUBSTITUTED PYRIDINYLPYRIMIDINE DERIVATIVES
JPH04154773A (en) * 1990-10-15 1992-05-27 Green Cross Corp:The Thiazole derivative
DE4117560A1 (en) * 1991-05-29 1992-12-03 Bayer Ag USE OF PYRIDINYLPYRIMIDINE DERIVATIVES TO PROTECT TECHNICAL MATERIALS
TW223004B (en) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5395817A (en) * 1992-01-22 1995-03-07 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
US5599774A (en) * 1992-01-22 1997-02-04 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
CA2131625A1 (en) * 1992-03-09 1993-09-16 Donald R. James Novel arylindazoles and their use as herbicides
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
CA2206315A1 (en) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
US6046136A (en) * 1997-06-24 2000-04-04 Zeneca Limited Herbicidal heterocyclic N-oxides compounds
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
JP3409029B2 (en) * 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Arylthiophene derivatives as PDEIV inhibitors
CA2331118A1 (en) * 1998-05-12 1999-11-18 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
WO2000006556A1 (en) * 1998-07-27 2000-02-10 Abbott Laboratories Substituted oxazolines as antiproliferative agents
ES2317889T3 (en) * 2000-03-01 2009-05-01 Janssen Pharmaceutica Nv DERIVATIVES OF TIAZOLIL 2,4-DISPOSED.

Also Published As

Publication number Publication date
AU2002362603A1 (en) 2003-04-07
CA2461363A1 (en) 2003-04-03
WO2003027094A2 (en) 2003-04-03
WO2003027095A1 (en) 2003-04-03
WO2003027107A1 (en) 2003-04-03
WO2003027085A2 (en) 2003-04-03
EP1432706A2 (en) 2004-06-30
WO2003027085A3 (en) 2003-12-04
WO2003027105A1 (en) 2003-04-03
WO2003027096A1 (en) 2003-04-03
EP1432698A2 (en) 2004-06-30
WO2003027094A3 (en) 2003-10-23
CA2461360A1 (en) 2003-04-03
JP2005532983A (en) 2005-11-04
JP2005528325A (en) 2005-09-22
WO2003027101A1 (en) 2003-04-03
WO2003027100A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2002340010A1 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
AU2002362895A1 (en) 5-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
AU2002346929A1 (en) 5-acylamino-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
AU2001251063A1 (en) 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AU2002303892A1 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
MXPA03006260A (en) Substituted amine derivatives and methods of use.
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
AU2001274009A1 (en) Substituted indoles as parp inhibitors
AU2001269939A1 (en) Methods for eliminating the formation of biofilm
AU2002357003A1 (en) Indoles as naaladase inhibitors
AU2002226911A1 (en) Indol derivative and their use as inhibitors of p38 kinase
HUP0500111A3 (en) Indolinone derivatives useful as protein kinase inhibitors
AU2002361861A1 (en) SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
PL369850A1 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
ZA200307306B (en) Indolines, substituted in portion 6, and their use as kinase inhibitors.
AU2001266648A1 (en) Kits and methods for optimizing the efficacy of chondroprotective compositions
AU2002230056A1 (en) Indole derivatives and their uses as heparanase inhibitors
AU2002334728A1 (en) Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
AU2002213830A1 (en) The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
AU2002334730A1 (en) Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
AU2002327756A1 (en) Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
AU2002337751A1 (en) Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
AU2002355325A1 (en) Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase